# Per Pfeiffer

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/per-pfeiffer/

## Facts

| Field | Value |
| --- | --- |
| Citations | 22,165 |
| Field | Colorectal Cancer Treatments and Studies |
| h-index | 60 |
| i10-index | 205 |
| Last Known Institution | University of Southern Denmark |
| OpenAlex ID | https://openalex.org/A5068848511 |
| ORCID iD | https://orcid.org/0000-0002-2925-0586 |
| Works | 547 |

## Researcher papers

- [Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis](https://scholariq.org/papers/effects-of-kras-braf-nras-and-pik3ca-mutations-on-the-efficacy-of-cetuximab-plus/)
- [Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial](https://scholariq.org/papers/short-course-radiotherapy-followed-by-chemotherapy-before-total-mesorectal/)
- [Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer](https://scholariq.org/papers/encorafenib-binimetinib-and-cetuximab-in-i-braf-i-v600e-mutated-colorectal/)
- [Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial](https://scholariq.org/papers/pembrolizumab-plus-chemotherapy-versus-placebo-plus-chemotherapy-for-her2/)
- [Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up](https://scholariq.org/papers/pancreatic-cancer-esmo-clinical-practice-guideline-for-diagnosis-treatment-and/)
- [Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus](https://scholariq.org/papers/efficacy-and-safety-of-pembrolizumab-for-heavily-pretreated-patients-with/)
- [Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial](https://scholariq.org/papers/ramucirumab-with-cisplatin-and-fluoropyrimidine-as-first-line-therapy-in/)
- [Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial](https://scholariq.org/papers/neoadjuvant-folfirinox-versus-upfront-surgery-for-resectable-pancreatic-head/)

## Researcher topics

- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Pancreatic and Hepatic Oncology Research](https://scholariq.org/topics/pancreatic-and-hepatic-oncology-research/)
- [Gastric Cancer Management and Outcomes](https://scholariq.org/topics/gastric-cancer-management-and-outcomes/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)

## Researcher university

- [University of Southern Denmark](https://scholariq.org/institutions/university-of-southern-denmark/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.